The effect of sitagliptin on total daily insulin dose, glycemic index and hypoglycemic attacks

The effect of sitagliptin on total daily insulin dose, glycemic index, and hypoglycemic attacks in patients with type 1 diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080902001181N3

Enrollment

Registered

2021-03-08

Start date

2021-03-20

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus. Type 1 diabetes mellitus without complications

Interventions

Intervention 1: Control group: Patients in this group will receive placebo in two doses of 50 mg daily for three months. Intervention 2: Intervention group: Patients in this group will receive 100 mg

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having type 1 diabetes treated with insulin, which takes less than 5 years to diagnose. Kidney failure (GFR> 50) Age range between 18 and 60 years Consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy Having a history of sitagliptin sensitivity Having a history of sitagliptin use in the last 6 months Body mass index (BMI) less than 18 kg/m2

Design outcomes

Primary

Measure	Time frame
Daily insulin dose. Timepoint: Before and after the intervention. Method of measurement: Daily registration.;Blood sugar. Timepoint: Before and after the intervention. Method of measurement: Using a glucometer device.;Hypoglycemic attacks. Timepoint: Before and after the intervention. Method of measurement: Number of occurrences (view).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMansour Siavash

Esfahan University of Medical Sciences

siavash@med.mui.ac.ir+98 31 3335 9933

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026